Keyphrases
Epstein-Barr Virus
100%
Protein Arginine Methyltransferase 5 (PRMT5)
79%
Mantle Cell Lymphoma
74%
Lymphoma Cells
39%
Lymphoproliferative Disorders
34%
Rituximab
34%
Natural Killer Cells
34%
Non-Hodgkin Lymphoma
33%
Lymphoma
27%
Post-transplant Lymphoproliferative Disorder
25%
Lymphoma Patients
24%
T Cells
24%
Chronic Lymphocytic Leukemia
23%
People Living with HIV (PLHIV)
20%
Diffuse Large B-cell Lymphoma (DLBCL)
17%
Complete Response
17%
Working Diagnosis
17%
Interleukin-2
17%
B Cells
17%
PRMT1
16%
Relapsed or Refractory
16%
CD74
15%
Progression-free Survival
15%
Milatuzumab
14%
Overall Survival
14%
Cyclin D1 (CCND1)
14%
Malignancy
14%
Ibrutinib
14%
Low-dose interleukin-2
13%
FTY720
13%
Flavopiridol
13%
Ethiopia
13%
Antiretroviral Therapy
13%
High Risk
13%
Cell Death
13%
Histone Deacetylase Inhibitor (HDACi)
13%
AIDS/HIV
13%
Methylation
12%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
12%
Immune-deficient Mice
12%
Kaposi Sarcoma
12%
Targeted Therapy
12%
Tumor
12%
Therapeutic Target
12%
B-cell Lymphoma
11%
HIV-associated Lymphoma
11%
Programmed Death-ligand 1 (PD-L1)
11%
Lymphomagenesis
11%
Vorinostat
10%
Classical Hodgkin Lymphoma
10%
Medicine and Dentistry
Epstein Barr Virus
55%
Mantle Cell Lymphoma
50%
B Cell
47%
Human Immunodeficiency Virus
46%
Non-Hodgkin Lymphoma
34%
Protein Arginine Methyltransferase 5
33%
Lymphoproliferative Disease
27%
Rituximab
24%
Malignant Neoplasm
23%
T Cell
22%
Disease
22%
In Vitro
19%
Cancer
19%
B-Cell Lymphoma
18%
Neoplasm
17%
Progression Free Survival
17%
Posttransplant Lymphoproliferative Disease
16%
Diffuse Large B-Cell Lymphoma
16%
Overall Survival
14%
B-Cell Chronic Lymphocytic Leukemia
14%
Milatuzumab
14%
Ibrutinib
14%
Immunity
14%
Transplantation
14%
Virus
13%
Programmed Cell Death
12%
Targeted Therapy
12%
Mantle Cell Lymphoma Cell
12%
Lymphoma Cell
11%
Natural Killer Cell
11%
Hematopoietic Cell
11%
Classical Hodgkin Lymphoma
10%
Central Nervous System
10%
Protein Arginine Methyltransferase
10%
Glioblastoma
10%
Vorinostat
10%
Fingolimod
10%
NK T Cell Lymphoma
10%
Virus DNA
9%
Kaposi Sarcoma
9%
Histone Deacetylase Inhibitor
8%
Cytotoxic T-Cell
8%
Lymphocyte
8%
Nivolumab
8%
Infection
8%
Oncology
8%
Cell Death
7%
CD20
7%
Langerhans Cell Histiocytosis
7%
Human Herpesvirus 8
7%
Immunology and Microbiology
Epstein Barr Virus
91%
B Cell
55%
Lymphoma Cell
43%
Natural Killer Cell
42%
T Cell
33%
Human Immunodeficiency Virus
33%
Interleukin 2
32%
Lymphoproliferative Disorders
24%
Rituximab
19%
SCID Mouse
19%
Cytokine
17%
Low Drug Dose
17%
Virus
16%
Peripheral Blood Lymphocyte
16%
Methylation
15%
Cytotoxic T-Cell
14%
Immunity
14%
CD74
14%
Hematopoietic Cell
14%
Lymphocyte
13%
Immunotherapy
11%
Milatuzumab
11%
Central Nervous System
10%
Immunology
10%
Blood Plasma
10%
Fingolimod
10%
DNA Virus
10%
Cell Death
9%
Progression Free Survival
8%
Overall Survival
8%
Interleukin 10
8%
Cell Survival
7%
Cell Line
7%
Cytotoxicity
7%
Drug Megadose
7%
CD20
7%
interferon
7%
Interleukin 15
7%
Mantle Cell Lymphoma Cell
7%
CD3 Antigen
7%
Cell Transformation
7%
Cell Transplantation
7%
Cancer Cell
6%
Multiple Myeloma
6%
Methotrexate
6%
Tumor-Associated Macrophage
6%
Acute Graft Versus Host Disease
6%
Chimeric Antigen Receptor T-Cell
6%
Mouse Model
6%
Natural Killer T Cell
6%